171 related articles for article (PubMed ID: 25301179)
21. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
Novotny L; Al-Tannak NF; Hunakova L
Neoplasma; 2016; 63(4):495-503. PubMed ID: 27268912
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
[TBL] [Abstract][Full Text] [Related]
23. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Chen Y; Peng C; Sullivan C; Li D; Li S
Anticancer Agents Med Chem; 2010 Feb; 10(2):111-5. PubMed ID: 20184539
[TBL] [Abstract][Full Text] [Related]
24. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.
Gandhi V; Plunkett W; Cortes JE
Clin Cancer Res; 2014 Apr; 20(7):1735-40. PubMed ID: 24501394
[TBL] [Abstract][Full Text] [Related]
25. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
26. A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected.
Winer ES; DeAngelo DJ
Oncol Ther; 2018 Jun; 6(1):9-20. PubMed ID: 32700137
[TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.
Kantarjian HM; O'Brien S; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):530-3. PubMed ID: 23790799
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.
Mahadeo KM; Cole PD
Blood; 2010 May; 115(18):3852. PubMed ID: 20448119
[No Abstract] [Full Text] [Related]
29. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
[TBL] [Abstract][Full Text] [Related]
30. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
[TBL] [Abstract][Full Text] [Related]
31. Homoharringtonine: a new treatment option for myeloid leukemia.
Luo CY; Tang JY; Wang YP
Hematology; 2004 Aug; 9(4):259-70. PubMed ID: 15621733
[TBL] [Abstract][Full Text] [Related]
32. Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Chen Y; Li S
Onco Targets Ther; 2014; 7():177-86. PubMed ID: 24516334
[TBL] [Abstract][Full Text] [Related]
33. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.
Wetzler M; Kantarjian HM; Nicolini FE; Lipton JH; Akard L; Baccarani M; Khoury HJ; Li E; Munteanu M; Cortes J
Blood Cancer J; 2015 Dec; 5(12):e376. PubMed ID: 26657200
[No Abstract] [Full Text] [Related]
34. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
35. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
36. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
Zhou M; Zeng J; Wang X; Guo Q; Huang T; Shen H; Fu Y; Wang L; Jia J; Chen C
J Transl Med; 2013 Oct; 11():265. PubMed ID: 24148180
[TBL] [Abstract][Full Text] [Related]
37. Integrating current treatment options for TKI-resistant chronic myeloid leukemia.
Radich JP; Shah NP; Mauro MJ
Clin Adv Hematol Oncol; 2014 Jul; 12(7 Suppl 13):3-17, 1. PubMed ID: 25768408
[TBL] [Abstract][Full Text] [Related]
38. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
39. Omacetaxine (Synribo) for CML.
Med Lett Drugs Ther; 2015 May; 57(1469):e80-1. PubMed ID: 26039555
[No Abstract] [Full Text] [Related]
40. Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?
Damlaj M; Assouline S
Leuk Lymphoma; 2015 Jan; 56(1):6-7. PubMed ID: 24898667
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
